In 2006, I-MAK began working to increase access to treatment for HIV in India. Today, the organization’s legal work and research has expanded to 49 countries and 33 therapies for 16 diseases, including hepatitis C, HIV, leukemia, tuberculosis, diabetes, cancer, and blood-related disorders. Worldwide, for HIV treatments alone, I-MAK has helped government health programs save more than $2 billion in the last 12 years.
Wins in China enable $50B in savings for hepatitis C treatment
In 2018, I-MAK successfully removed unmerited patents on Solvadi, the backbone of hepatitis C treatment. This victory for the 10 million people living with hepatitis C in China could save $50 billion to the health system if only 59% of infections are treated (similar to treatment rate for HIV).
Reduced prices for HIV drugs in India, catalyzing savings worldwide
As a result of I-MAK’s successful patent challenges on four HIV drugs in India, prices for these lifesaving generic medicines are now 51-89% lower than the branded versions. These wins supplied low and middle income countries worldwide with low-cost generics, saving an estimated $500 million – money that could be reinvested to treat more than one million people.
Public health programs save half a billion dollars per year in four countries
I-MAK has worked alongside five patient advocacy organizations since 2014 to reduce drug prices in Argentina, Brazil, Thailand, and Ukraine.* Patent challenges, drug pricing negotiations, and policy dialogues between the public and private sectors on 15 HIV drugs in these four countries have contributed to price reductions in four countries, which are saving health programs an estimated $472 million each year.